Rheumatology Advance Access originally published online on July 10, 2007
Rheumatology 2007 46(9):1450-1453; doi:10.1093/rheumatology/kem166
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-
antibody infliximab
Rheumazentrum Ruhrgebiet, Herne, Ruhr-University Bochum, 1Rheumatology, Charité, Campus Benjamin Franklin and 2German Rheumatism Research Center, Berlin, Germany.
Correspondence to: Prof. Dr J. Braun, Rheumazentrum Ruhrgebiet, Landgrafenstr.15, 44652 Herne, Germany. E-mail: j.braun{at}rheumazentrum-ruhrgebiet.de
 |
Abstract |
|---|
Objectives. Anti-tumour necrosis factor therapy with infliximab has been shown to improve signs and symptoms of patients with active ankylosing spondylitis (AS). The objective of this article was to study the effect of infliximab on structural changes in AS over 4 yrs.
Methods. Conventional radiographs of the cervical and the lumbar spine of 33 AS patients at baseline (BL), after 2 (FU1) and after 4 yrs (FU2) of infliximab therapy were scored by the modified Stokes ankylosing spondylitis spinal score (mSASSS). Definite baseline damage was defined when at least one syndesmophyte (mSASSS 
2) was seen. Definite radiographic progression was defined as a change from 0 or 1 to syndesmophytes or ankylosis (mSASSS 2).
Results. The mean change over 4 yrs was 1.6 ± 2.6 mSASSS units (P = 0.001), (0.9 ± 2.3 for BL–FU1 vs 0.7 ± 1.6 for FU1–FU2). This is less radiographic progression in comparison with published data from the OASIS cohort (4.4 within 4 yrs). Definite radiographic progression was found in 10/33 (30.3%) patients for BL–FU2. Patients with definite damage at BL developed more chronic changes at FU2 (2.3 ± 3.1, P = 0.003) than those with no damage at BL (0.7 ± 1.5, P = 0.08). Four out of seven patients with no damage at BL showed radiographic deterioration after 4 yrs. The change of the mean mSASSS in comparison with BL was significantly different after 2 (P = 0.007) but not after 4 yrs of infliximab therapy.
Conclusions. There is some radiographic progression after 2 and 4 yrs of infliximab therapy in AS patients. A comparison with the historical OASIS cohort suggests that infliximab may decelerate progression of structural changes. Larger studies are needed to confirm this finding.
KEY WORDS: Ankylosing spondylitis, Infliximab, X-rays, Chronic spinal changes, mSASSS
Submitted 10 January 2007;
revised version accepted 14 May 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Keat Sex and the spondylitic Rheumatology, November 1, 2009; 48(11): 1337 - 1338. [Full Text] [PDF]
|
|
|
|
|
|
D. Elewaut and M. Matucci-Cerinic Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice Rheumatology, September 1, 2009; 48(9): 1029 - 1035. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. BARALIAKOS, J. LISTING, A. von der RECKE, and J. BRAUN The Natural Course of Radiographic Progression in Ankylosing Spondylitis -- Evidence for Major Individual Variations in a Large Proportion of Patients J Rheumatol, May 1, 2009; 36(5): 997 - 1002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Braun and J. Sieper What is the most important outcome parameter in ankylosing spondylitis? Rheumatology, December 1, 2008; 47(12): 1738 - 1740. [Full Text] [PDF]
|
|
|
|
|
|
T. Haupl, M. Ostensen, A. Grutzkau, G.-R. Burmester, and P. M. Villiger Interaction between rheumatoid arthritis and pregnancy: correlation of molecular data with clinical disease activity measures Rheumatology, June 1, 2008; 47(suppl_3): iii19 - iii22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. U. Lories, I. Derese, and F. P. Luyten Inhibition of osteoclasts does not prevent joint ankylosis in a mouse model of spondyloarthritis Rheumatology, May 1, 2008; 47(5): 605 - 608. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Keat, K. Gaffney, A. K. Gilbert, C. Harris, and J. Leeder Influence of biologic therapy on return to work in people with work disability due to ankylosing spondylitis Rheumatology, April 1, 2008; 47(4): 481 - 483. [Abstract] [Full Text] [PDF]
|
|